Aileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary Fibrosis
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
The American Journal of Managed Care2h
Liver Fibrosis Scores May Hint at Heart Failure Risk
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over 15 Companies are Progressing Through to Improve the Treatment Landscape | DelveInsight
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
Berlin21h
Over 900: Coronavirus incidence in Berlin continues to rise
A week ago, the incidence had been at 511.5. In a comparison of the federal states, only Bremen has a higher seven-day incidence than Berlin. Not included in the Berlin figures are data from ...